Tumor MicroRNA expression profiling identifies circulating MicroRNAs for early breast cancer detection

Clinical Chemistry

Volumn 61, Issue 8, 2015, Pages 1098-1106

  Matamala, Nerea ^a   Vargas, María Teresa ^c   González Cámpora, Ricardo ^b   Miñambres, Rebeca ^c   Arias, JoséIgnacio ^d   Menéndez, Primitiva ^e   Andrés León, Eduardo ^h   Mez López, Gonzalo Gómez ^f   Yanowsky, Kira ^a   Calvete Candenas, Julio ^g   Inglada Pérez, Lucía ^a,b   Martínez Delgado, Beatriz ^c   Benítez, Javier ^a,b  

^a Human Cancer Genetics Programme   (United States)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d Sistemas Genomicos   (Spain)

^e HOSPITAL MONTE NARANCO   (Spain)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^g Instituto de Salud Carlos III   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 125B; MICRORNA 141; MICRORNA 142; MICRORNA 183; MICRORNA 200A; MICRORNA 21; MICRORNA 3656; MICRORNA 505; MICRORNA 96; UNCLASSIFIED DRUG; MIRN505 MICRORNA, HUMAN; MIRN96 MICRORNA, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER DIAGNOSIS; CONTROLLED STUDY; DEREGULATION; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UPREGULATION; BLOOD; CLINICAL TRIAL; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; MULTICENTER STUDY; PATHOLOGY; REFERENCE VALUE; REPRODUCIBILITY;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84938820044     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.238691     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10 -29.
2. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast us and evaluation of factors that influence them: An analysis of 27, 825 patient evaluations. Radiology 2002;225:165-75.
3. Sharp PC, Michielutte R, Freimanis R, Cunningham L, Spangler J, Burnette V. Reported pain following mammography screening. Arch Intern Med 2003;163: 833- 6.
4. Law J, Faulkner K. Cancers detected and induced, and associated risk and benefit, in a breast screening programme. Br J Radiol 2001;74:1121-7.
5. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
6. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009;136:215-33.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834 - 8.
8. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
9. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654 -9.
10. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011; 108:5003- 8.
11. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010;5:e13515.
12. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 2013;132:1602-12.
13. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 2013;19: 4477- 87.
14. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010;12:R90.
15. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics re-search. Behav Brain Res 2001;125:279 - 84.
16. Romualdi C, Campanaro S, Campagna D, Celegato B, Cannata N, Toppo S, et al. Pattern recognition in gene expression profiling using DNA array: A comparative study of different statistical methods applied to cancer classification. Hum Mol Genet 2003;12:823-36.
17. Wessels LF, Reinders MJ, Hart AA, Veenman CJ, Dai H, He YD, van't Veer LJ. A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics 2005;21:3755- 62.
18. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65: 7065-70.
19. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257- 61.
20. Huang GL, Zhang XH, Guo GL, Huang KT, Yang KY, Shen X, et al. Clinical significance of miR-21 expression in breast cancer: SYBR-green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 2009; 21:673-9.
21. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J BiolChem 2008;283:1026 -33.
22. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007;282:14328 -36.
23. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, et al. MiR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011;71: 3552- 62.
24. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 2011; 128:1758 - 69.
25. Guan Y, Yao H, Zheng Z, Qiu G, Sun K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer 2011;128:2274 - 83.
26. Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010;16:991-1006.
27. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011;57:84 -91.
28. Mar-Aguilar F, Mendoza-Ramirez JA, Malagon- Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz- Flores P, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 2013;34:163-9.
29. Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, Hu C. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 2013;139:223-9.
30. Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 2013;8:e53141.
31. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol 2012;138:1659 - 66.
32. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, Luo H. Circulating miR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012;7:e34210.
33. Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T, et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Molec Cancer 2011;10:135.
34. Li P, Sheng C, Huang L, Zhang H, Huang L, Cheng Z, Zhu Q. MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. Breast Cancer Res 2014;16:473.